Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 83NETWORK 24NIH 23INDUSTRY 4OTHER_GOV 2

Study Type

Observational 23Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Lymphoid 1Gastrointestinal 1

Conditions

Pathologic Complete Response 1Leukemia, Myeloid, Acute 1Leukemia, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Observation × Clear all
NCT04229979 2025-10-01

REGAL

Sellas Life Sciences Group

Phase 3 Active not recruiting
127 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT03770299 2022-03-24

CheckMate 9TN

Bristol-Myers Squibb

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01039376 2019-07-30

PROLONG

Novartis

Phase 3 Terminated
480 enrolled 30 charts
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT00759109 2017-04-07

Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)

Merck Sharp & Dohme LLC

Phase 3 Completed
150 enrolled 12 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡